American Society of Clinical Oncology (ASCO) shared a post on X:
“Shaalan Beg and David Wang recap key studies from GI25 and highlight research on CRC, esophageal cancer, ctDNA and more on the latest episode of the ASCO Daily News Podcast.”
Shaalan Beg, Senior Advisor for Clinical Research at National Cancer Institute, shared this post, adding:
“Update on this:
Breakwater trial shows significant survival advantage to targeted therapy for BRAF mutated colorectal cancer.”
More posts featuring ASCO and Shaalan Beg.
